Compare ABM & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ABM | PRCT |
|---|---|---|
| Founded | 1909 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.0B |
| IPO Year | N/A | 2021 |
| Metric | ABM | PRCT |
|---|---|---|
| Price | $46.63 | $36.33 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $55.25 | $51.50 |
| AVG Volume (30 Days) | 480.3K | ★ 1.6M |
| Earning Date | 12-17-2025 | 11-04-2025 |
| Dividend Yield | ★ 2.27% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.84 | N/A |
| Revenue | ★ $8,627,900,000.00 | $299,907,000.00 |
| Revenue This Year | $5.43 | $48.34 |
| Revenue Next Year | $3.15 | $29.35 |
| P/E Ratio | $25.29 | ★ N/A |
| Revenue Growth | 4.27 | ★ 50.07 |
| 52 Week Low | $40.00 | $27.80 |
| 52 Week High | $57.33 | $92.92 |
| Indicator | ABM | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 68.89 | 62.12 |
| Support Level | $44.14 | $33.27 |
| Resistance Level | $44.72 | $38.11 |
| Average True Range (ATR) | 0.77 | 1.83 |
| MACD | 0.53 | 0.72 |
| Stochastic Oscillator | 88.29 | 80.10 |
ABM Industries Inc is a provider of integrated facility solutions. It offers its solutions through five segments: Business and Industry, Manufacturing and Distribution, Education, Aviation and Technical solutions. The company derives the majority of its revenue from the business and industry segment, which encompasses janitorial, facilities engineering, and parking services for commercial real estate properties and sports and entertainment venues, hospitals, as well as vehicle maintenance and other services to rental car providers. The company mainly operates in the United States of America.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.